Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

At Last, AZ’s Imfinzi/Tremelimumab Cancer Combo Shows Survival Benefit

Could Signal First Tremelimumab Approval

Executive Summary

After five years of failure in NSCLC trials, AstraZeneca’s immunotherapy combo shows survival benefits in POSEIDON.

You may also be interested in...



AstraZeneca’s Imfinzi/Treme Combo Fails To Match Leaders In First-Line Lung Cancer

The immunotherapy drugs fall short of the standard set by Keytruda, but could gain some traction in non-squamous patient group.

CASPIAN Proves Too Choppy For AZ Imfinzi/Tremelimumab Combo

Another day and another fail for AstraZeneca's combination of Imfinzi and tremelimumab, this time for extensive-stage small-cell lung cancer.

New Data Bolster Tecentriq Bid To Be First Adjuvant Immunotherapy In NSCLC

Roche presents further analysis on Tecentriq’s potential first-in-class adjuvant use, which could add up to $3bn a year to revenues.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144321

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel